Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Clin Cancer Res. 2021 Feb 19;27(13):3528–3539. doi: 10.1158/1078-0432.CCR-20-4465

Figure 2: Therapeutic strategies to target HER3.

Figure 2:

The most popular strategies to target HER3 have been monoclonal and bispecific antibodies, as well as pan-HER strategies. Emerging strategies to target HER3 include antibody drug conjugates, HER3-targeting vaccines, and different ways to affect HER3 degradation either in mRNA or protein level. Epigenetic inhibitors could potentially be useful for inhibiting HER3 gene expression, although the mechanisms and feasibility of these strategies will have to be further validated. EGFR: Epidermal growth factor receptor, HER2: Human epidermal growth factor receptor 2, HER3: Human epidermal growth factor receptor 3, NRG: Neuregulin, mAbs: Monoclonal antibodies, IGFR: Insulin-like growth factor receptor. DXd: DX-8951 derivative.